AI-powered search
a

Previous Tx in Metastatic Melanoma May Cut Response to ACT TIL

Prior therapy linked to lower objective response rate to adoptive cell transfer with tumor-infiltrating lymphocytes compared with no prior therapy

By Physician’s Briefing Staff | August 19, 2021

The researchers found that in patients naive to PD-1 therapy, adoptive transfer of TILs mediated an objective response rate of 56 percent and median melanoma-specific survival of 28.5 months compared with 24 percent and 11.6 months, respectively, in patients refractory to aPD-1. Compared with patients naive to targeted therapy, prior treatment with targeted molecular therapy was associated with a reduced response rate (21 versus 60 percent) and decreased survival (9.3 versus 50.7 months) among patients with BRAF V600E/K-mutated disease.

"If you wait to use ACT-TIL as a later-line therapy, you may not get the same durable responses as when you use it up front," a coauthor said in a statement. "We should think about utilizing TILs earlier in the disease course."

Two authors disclosed financial ties to biopharmaceutical companies, including Iovance Biotherapeutics, which partially funded the study.

Abstract/Full Text (subscription or payment may be required)

HealthDay

Copyright © 2021 HealthDay. All rights reserved.
Loading...
Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved